[1] CARSON S W.Pharmacokinetic and pharmacodynamic drug interactions with polypharmocotherapy of treatment-resistant affective and obsessive-compulsive disorders[J] .Psycopharmacol Bull，1996，32 ：555-568. [2] SHADER R I， VON MOLTKE L L， SCHMIDER J， et al.The clinician and drug interactions an update[J] .J Clin Psychopharmacol， 1996， 16： 197-201. [3] POND S M， GRAHAM G G， BIRKETT D J， et al. Effects of tricyclic antidepressants on drug metabolism[J] .Clin Pharmacol Ther，1975，18(2)： 191-199. [4] THOMPSON D S， SWEET R A， MARZULA K， et al. Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient[J] .J Clin Psychopharmacol，1997，17(4)： 322-323. [5] FLEISHAKER J C， RYAN K K， JANSAT J M， et al. Effect of MAO2A inhibition on the pharmacokinetics of almotriptan， an antimigraine agent in humans[J] .Br J Clin Pharmacol， 2001， 51： 437-441. [6] HARVEY P.Cytochrome P450 enzymes： interpretation of their interactions with selective serotonin reuptake inhibitors.Part Ⅰ[J] . J Clin Psychopharmacol，1996，16 ：273-285. [7] NELSON M H， BIRNBAUM A K， REMMEL R P.Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors[J] .Epilepsy Res，2001，44(1)： 71-82. [8] CAI W M， CHEN B， ZHOU Y， et al. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers[J] .Clin Pharmacol Ther，1999， 66(5)： 516-521. [9] LEIBOVITZ A， BILCHINSKY T， GIL I， et al. Elevated serum digoxin level associated with coadministered fluoxetine[J] .Arch Intern Med，1998，158(10)： 1152-1153. [10] HORTON R C， BONSER R S.Interaction between cyclosporin and fluoxetine[J] .BMJ，1995， 311(7002)： 422. [11] MAMIYA K， KOJIMA K， YUKAWA E， et al.Phenytoin intoxication induced by fluvoxamine[J] .Ther Drug Monit，2001，23 ：75-77. [12] KUSUMOTO M， UENO K， ODA A， et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men[J] .Clin Pharmacol Ther，2001，69 ：104-107. [13] LI Z D.Fluvoxamine and warfarin interaction：inhibition of CYP1A2[J] .Advese Drug React J（药物不良反应杂志），2001，69：104~107. [14] JEPPESEN U， LOFT S， POULSEN H E， et al. A fluvoxamine-caffeine interaction study [J] .Pharmacogenetics，1996，6(3)： 213-222. [15] RASMUSSEN B B，JEPPESEN U，GAISTT D， et al.Riseofulvin and fluvoxamine interactions with the metabolism of theophylline[J] .Ther Drug Monit，1997，19(1)： 56-62. [16] CHANG W H，AUGUSTIN B，LANE H Y， et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine[J] .Psychopharmacology(Berl)，1999，145(1)： 91-98. [17] VELLA J P， SAYEGH M H.Interactions between cyclosporine and newer antidepressant medications[J] .Am J Kidney Dis，1998，31(2)： 320-323. [18] ALDERMAN C P， GEBAUER M G， GILBERT A L， et al. Possible interaction of zopiclone and nefazodone[J] .Ann Pharmacother，2001，35： 1378-1380. [19] ABERNETHY D R， BARBEY J T， FRANC J， et al. Loratadine and terfenadine interaction with nefazodone： Both antihistamines are associated with QTc prolongation[J] .Clin Pharmacol Ther， 2001， 69 ： 96-103. [20] OLYAEI A J， DEMATTOS A M， NORMAN D J， et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient[J] .Pharmacotherapy，1998，18(6)： 1356-1359. [21] CAMPO J V， SMITH C， PEREL J M.Tacrolimus toxic reaction associated with the use of nefazodone： paroxetine as an alternative agent[J] .Arch Gen Psychiatry，1998，55(11)： 1050-1052. [22] DOCKENS R C， GREENE D S， BARBHAIYA R H.Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers[J] .J Clin Pharmacol，1996，36(2)： 160-167. [23] LEVIN G M， NELSON L A， DEVANE C L， et al. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir[J] .Psychopharmacol Bull，2001，35(2)： 62-71. [24] ANTTILA A K， RASANEN L， LEINONEN E V.Fluvoxamine augmentation increases serum mirtazapine concentrations three to fourfold[J] .Ann Pharmacother， 2001， 35： 1221-1223. [25] HERMAN B D， FLEISHAKER J C， BROWN M T.Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans[J] .Clin Pharmacol Ther，1999， 66(4)： 374-379. [26] SUN J H， ZHU X Q.Progresses and application of the researches on the correlation between pregnane X receptor and CYP3A[J] . Chin J Pharmacol Toxicol（中国药理学与毒理学杂志），2003， 17(3)： 235-240. [27] MOORE L B， GOODWIN B， JONES S A， et al. St.John′s wort induces hepatic drug metabolism through activation of the pregnane X receptor[J] .Proc Natl Acad Sci USA， 2000， 97 (13)： 7500-7502. [28] DURR D， STIEGER B， KULLAK-UBLICK G A， et al. St John′s wort induces intestinal P-glycoprotein/ MDR1 and intestinal and hepatic CYP3A4[J] .Clin Pharmacol Ther， 2000， 68： 598-604. [29] CHENG T O.St John′s wort interaction with digoxin [J] .Arch Intem Med，2000，160：2548. [30] BREIDENBACH T H， HOFFMANN M W， BECKER T H， et al. Drug interaction of St John′s wort with ciclosporin[J] .Lancet，2000， 355(9218)：1912. [31] MONIQUE M R， RICHARD M W， RON A A， et al. Drug interaction between St John′s wort and nevirapine[J] .Aids， 2001， 15 (3)： 420-421. [32] YUE Q Y， BERGQUIST C， GERDEN B.Safety of St John′s wort ( Hypericum perforatum) [J] .Lancet，2000，355 (9203)：575-577. [33] ROOTS I， JOHNE A， SCHMIDER J， et al. Interaction of a herbal extract from St John′s wort with amitryptiline and its metabolites [J] .Clin Pharmacol Ther，2000， 67 (2)：159.